Protocole National de Diagnostic et de Soins (PNDS)

Le spectre des maladies à anticorps anti-MOG

Argumentaire

Octobre 2022

Centre de Référence Maladies Inflammatoires Rares du Cerveau Et de la Moelle

MIRCEM
Maladies Inflammatoires Rares du Cerveau et de la Moelle

Membre de la
Filière de Santé Maladies Rares du système nerveux central BRAIN-TEAM

filière de santé maladies rares

BRAIN-TEAM
Filière Nationale de Santé
Maladies rares du système nerveux central

Cet argumentaire a été élaboré par le Centre de Référence Maladies Inflammatoires Rares du Cerveau Et de la Moelle. Il a servi de base à l'élaboration du PNDS Le spectre des maladies à anticorps anti-MOG (MOGAD).
Le PNDS est téléchargeable sur le site du centre de référence www.mircem.fr

Sommaire

Liste des abréviations

AQP4	aquaporine-4
CLIPPERS	Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids
FLAIR	Fluid Attenuated Inversion Recovery
FLAMES	FLAIR-hyperintense lesions in anti-MOG associated encephalitis with seizures
MOG	Myelin Oligodendrocyte Glycoprotein
MOGAD	Maladies à Anticorps anti-MOG
NMOSD	Maladies du Spectre de la Neuromyélite Optique
NO	Névrite Optique
NOI	Névrites Optiques Inflammatoires
OCT	Optical Coherence Tomography
PNDS	Protocole National de Diagnostic et de Soins
SEP	Sclérose En Plaques
SNC	Système Nerveux Central

Préambule

Le PNDS sur le spectre des maladies à anticorps anti-MOG (MOGAD) a été élaboré selon la « Méthode d'élaboration d'un protocole national de diagnostic et de soins pour les maladies rares » publiée par la Haute Autorité de Santé en 2012 (guide méthodologique disponible sur le site de la HAS : www.has-sante.fr).
Le présent argumentaire comporte l'ensemble des données bibliographiques analysées pour la rédaction du PNDS.

Argumentaire

Recommandations et conférences de consensus (bonnes pratiques)

Il n'existe aucune recommandation et conférences de consensus de prise en charge des patients atteints de MOGAD chez l'adulte. Par contre, chez l'enfant, le consensus européen de 2020 propose une prise en charge.

Auteur, référence, année	Titre	Thème	Commentaire
Névrite optique à anticorps anti MOG chez l'adulte et l'enfant			
Biotti D, Bonneville F, Tournaire E, et al. J Neurol. 2017 Oct;264(10):2173-2175.	Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France	Revue	Revue des symptômes cliniques et radiologiques des NO chez les patients MOGAD
Bruijstens AL, Breu M, Wendel EM, et al. Eur J Paediatr Neurol. 2020 Nov;29:32-40.	E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders	Revue secondaire au consensus européen pédiatrique	Revue complète sur les MOGAD en pédiatrie
Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, et al. Eur J Paediatr Neurol. 2020 Nov;29:2-13	E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.	Revue secondaire au consensus européen pédiatrique	Revue complète sur les MOGAD en pédiatrie
Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Am J Ophthalmol. 2018 Nov;195:8-15.	Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.	Revue	Revue des symptômes cliniques et radiologiques des NO chez les patients MOGAD
Cheuret E, Meyer P, Varenne F et al. Journal de Pédiatrie et de Puériculture. 2021 June, 34 : 115-121.	Prise en charge de la neuropathie optique inflammatoire de l'enfant.	Article de journal	Arbre
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Neurology. 2018 May 22;90(21):e1858–69.	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.	Revue	Revue des symptômes cliniques et biologiques des NO chez les patients MOGAD
Deschamps R, Pique J, Ayrignac X, et al NOMADMUS study group. Eur J Neurol. 2021 May;28(5):1659-1664	The long-term outcome of MOGAD: An observational national cohort study of 61 patients.	Revue	Revue sur l'évolution et pronostic des patients MOGAD
Ducloyer JB, Caignard A, Aidaoui R, et al. Br J Ophthalmol. 2020 Jun;104(6):842-845	MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis.	Revue	Revue sur les NO des patients MOGAD
Havla J. et al. J. Neuroinflammation 18, 121 (2021).	Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?	Revue	Revue sur des facteurs prédictifs des NO des patients MOGAD
Kohji Azumagawa K et al. Brain and Development, 2021 June; 43 (6):705-713.	A nation-wide survey of Japanese pediatric MOG antibody-associated diseases.	Revue	Revue sur des patients pédiatriques MOGAD au Japon
Korobelnik JF. Présentation à la Société française d'ophtalmologie Elsevier Masson, 2019	OCT en ophtalmologie : rapport 2019 présenté à la Société française d'ophtalmologie	Présentation orale	Apport de l'OCT dans les NO inflammatoires

Lotan I, Brody J, et al. J Neurol. 2018 Sep;265(9):1985-1988.	Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation.	Revue	5 cases reports de NO pseudo-tumorales chez des patients MOGAD
Merabtene L, Vignal Clermont C, Deschamps R. J Fr Ophtalmol. 2019 Dec;42(10):1100-1110.	Neuropathie optique dans le syndrome des anticorps anti MOG positif	Article d'un journal ophtalmologique	1 case report d'une NO à anticorps anti-MOG sévère
Shor N, Aboab J, Maillart E, et al. Eur J Neurol. 2020 Feb;27(2):384-391	Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients.	Revue	Revue des NO chez 62 patients adultes MOGAD
Toanen V, Vignal-Clermont C (2016) www.em-premium.com/data/traites/op/21-71372.	Neuropathies optiques inflammatoires.	Article	Présentation des NO chez les patients MOGAD
Vignal-Clermont C. Elsevier Masson	Neuro-ophtalmologie pratique, rapport SFO 2020.	Présentation orale	Présentation des atteintes optiques inflammatoires
Vosoughi AR, Ling J, Tam KT, et al. Br J Ophthalmol doi:10.1136/ bjophthalmol-2020-317267	Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review	Revue	Revue des NO chez des patients MOGAD
Wendel. EM et al. Eur J Paediatr Neurol. 2020 Jul;27:86-93	High association of MOG-IgG antibodies in children with bilateral optic neuritis.	Revue	Revue des NO chez des patients pédiatriques MOGAD
Myélites à anticorps anti-MOG chez l'adulte et l'enfant			
Absoud M, Greenberg BM, Lim M, Lotze T, Thomas T, Deiva K. Neurology. 2016;87(9 Suppl 2):S46-S52	Pediatric transverse myelitis.	Revue	Revue sur les myélites inflammatoires
Chien C, Scheel M, Schmitz-Hübsch T et al Mult Scler 2019; 25: 1926-36	Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity	Revue	Revue sur les atteintes médullaires des NMOSD AQP4+ et MOG+
Ciron J, Cobo-Calvo A, Audoin B et al. Mult Scler 2020; 26: 936-44	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.	Revue	Revue comparative des atteintes limitées et étendues des patients MOGAD
Dubey D, Pittock SJ, Krecke KN et al., JAMA Neurol 2019; 76: 3019-9	Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody.	Revue	Revue sur les myélites des patients MOGAD
Group TMCW. Neurology. 2002;59(4):499-505.	Proposed diagnostic criteria and nosology of acute transverse myelitis.	Revue	Revue sur des critères diagnostiques des myélites
Jurynczyk M, Jacob A, Fujihara K and Palace J. Pract Neurol 2019; 19: 187-95	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.	Revue	Revue sur les myélites des patients MOGAD

Jurynczyk M, Messina S, Woodhall MR, et al. Brain. 2017;140(12):3128-3138.	Clinical presentation and prognosis in MOG-antibody disease: a UK study.	Revue	Revue sur les myélites des patients MOGAD en Angleterre
Kitley J, Waters P, Woodhall M et al., JAMA Neurol 2014; 71: 276-83	Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.	Revue	Revue comparative des patients NMOSD AQP4+ et MOG+
Lechner C, Baumann M, Hennes E-M, et al. J Neurol Neurosurg Psychiatr. 2016;87(8):897-905.	Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.	Revue	Revue comparative des patients enfants NMOSD AQP4+ et MOG+
Macaron G and Ontaneda D. Mutl Scler 2020; 26: 515-15	MOG-related disorders: A new cause of imaging-negative myelitis?	Revue	Case report d'une myélite à IRM normale chez un patient MOGAD
Maynard FM, Bracken MB, Creasey G, et al. American Spinal Injury Association. Spinal Cord. 1997;35(5):266-274	International Standards for Neurological and Functional Classification of Spinal Cord Injury.	Revue	Revue sur la classification des myélites
Rabasté S, Cobo-Calvo A, Nistiriuc-Muntean V et al., J Neuroradiol 2021; 48: 28-36	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy.	Revue	Revue sur les « bright spotty lesions » dans les NMOSD AQP4+
Ramanathan S, Mohammad S, Tantsis E, et al. J Neurol Neurosurg Psychiatr. 2018;89(2):127-137.	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.	Revue	Revue sur les patients MOGAD
Sato DK, Callegaro D, Lana-Peixoto MA et al., Neurol 2014; 82: 474-81	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.	Revue	Revue comparative des NMOSD AQP4+ et NMOSD MOG+
Sechi E, Krecke KN, Pittock SJ et al., Mult Scler 2021; 27: 303-308	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.	Revue	Revue de myélite à IRM normale chez des patients MOGAD
Shor N, Deschamps R, Cobo Calvo A, Maillart E, Zephir H, Ciron J, et al. Rev Neurol (Paris). 2021 Jan;177(1–2):39–50.	MRI characteristics of MOG-Ab associated disease in adults: An update.	Revue	Revue sur les patients MOGAD
Atteintes encéphaliques à anticorps anti-MOG chez l'adulte et l'enfant			
Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265–72.	Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein	Revue	Revue comparative des encéphalites inflammatoires MOG+ et MOG- chez l'enfant
Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. J Neurol. 2019 Oct;266(10):2481–7.	Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome	Revue	Case report + revue sur les FLAMES corticales unilatérales
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al.	Clinical spectrum and prognostic value of CNS MOG	Revue	Revue de patients MOGAD adultes

Neurology. 2018 May 22;90(21):e1858–69.	autoimmunity in adults: The MOGADOR study.		
Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Ann Neurol. 2021 Jan;89(1):30–41.	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.	Revue	Revue rétrospective des rechutes chez les patients MOGAD
Fadda G, Banwell B, Waters P, Marrie RA, Yeh EA, O'Mahony J, et al. Ann Neurol. 2021 Feb;89(2):408–13	Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease.	Revue	Revue sur les progressions radiologiques asymptomatiques chez les patients MOGAD
Fujimori J, Nakamura M, Yagihashi T, Nakashima I. Front Neurol. 2020 Dec 16;11:600169	Clinical and Radiological Features of Adult Onset Bilateral Medial Frontal Cerebral Cortical Encephalitis With Anti-myelin Oligodendrocyte Glycoprotein Antibody.	Revue	Revue sur les encéphalites corticales cérébrales frontales médiales bilatérales chez les patients MOGAD
Netravathi M, Holla VV, Nalini A, Yadav R, Vengalil S, et al. J Neurol. 2021 Apr;268(4):1419–33.	Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.	Revue	Revue sur les patients MOGAD
Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. Neurol - Neuroimmunol Neuroinflammation. 2017 Mar;4(2):e322.	MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.	Revue	Revue sur les encéphalites corticales chez les patients adultes MOGAD
Ramberger M, Bsteh G, Schanda K, Höftberger R, Rostásy K, Baumann M, et al. Neurol - Neuroimmunol Neuroinflammation. 2015 Oct;2(5):e141.	NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases.	Revue	Revue sur la rare positivité des NMDA-R chez les patients atteints de maladie démyélinisante
Shor N, Deschamps R, Cobo Calvo A, Maillart E, Zephir H, Ciron J, et al. Rev Neurol (Paris). 2021 Jan;177(1–2):39–50.	MRI characteristics of MOG-Ab associated disease in adults: An update.	Revue	Revue sur les atteintes radiologiques chez les patients adultes MOGAD
Yazbeck E, Maurey H, Leroy C, Horellou P, Napuri S, et al. Neuropediatrics. 2021 Aug;52(4):337–40	Progressive Leukodystrophy-Like Demyelinating Syndromes with MOG-Antibodies in Children: A Rare Under-Recognized Phenotype.	Case report	Case report d'un enfant MOGAD avec régression cognitive et progression radiologique
Atteintes du tronc cérébral à anticorps anti-MOG chez l'adulte et l'enfant			
Banks SA, Morris PP, Chen JJ, et al. J Neurol Neurosurg Psychiatry 2020.	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS.	Revue	Revue comparative des atteintes sous tentorielles des patients MOGAD, NMOSD AQP4 et SEP
Berzero G, Taieb G, Marignier R, et al. Eur J Neurol 2018;25:e16-e17	CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies.	Revue	Revue sur les CLIPPERS chez les patients MOGAD
Cobo-Calvo A, Ayrignac X, Kerschen P, et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e543.	Cranial nerve involvement in patients with MOG antibody-associated disease.	Revue	Revue sur les atteintes crâniennes chez des patients MOGAD

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, et al. Neurology. 2018 May 22;90(21):e1858–69.	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.	Revue	Revue sur les patients adultes MOGAD, facteurs pronostiques et taux d'anticorps anti-MOG.
Fujimori J, Takahashi T, Matsumoto Y, et al. J Neuroimmunol 2019;334:577002.	Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behcet's disease.	Revue	Case report sur 2 patients japonais MOGAD proche neuro-Behçet
Jarius S, Kleiter I, Ruprecht K, et al. J Neuroinflammation 2016;13:281.	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.	Revue	Revue sur les atteintes sous tentorielles de patients MOGAD
Kaneko K, Sato DK, Nakashima I, et al. J Neurol Neurosurg Psychiatry 2018;89:927-936.	CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.	Revue	Revue comparative des paramètres biologiques des patients MOGAD, NMOSD AQP4 et SEP
Kunchok A, Krecke KN, Flanagan EP, et al. Neurology 2020;94:85-88.	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?	Revue	Revue sur le syndrome de l'area postrema dans les MOGAD
Rinaldi S, Davies A, Fehmi J, et al. Neurol Neuroimmunol Neuroinflamm 2021;8.	Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders.	Revue	Revue des atteintes cliniques des MOGAD
Salama S, Khan M, Levy M, Izbudak I. Mult Scler Relat Disord 2019;29.	Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.	Revue	Revue des atteintes radiologiques des MOGAD
Shen Y, Cheng Z, Zhou C. Neurol Sci 2019;40:1083-1085.	Bilateral trigeminal root entry zone enhancement in MOG-IgG-associated brainstem encephalitis.	Revue	Revue des atteintes des nerfs crâniens des MOGAD
Taieb G, Labauge P. Neurology 2015;85:1262-1263.	Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS.	Revue	Revue des atteintes cliniques des MOGAD
Vecchio D, Virgilio E, Naldi P, Comi C, Cantello R. Mult Scler Relat Disord 2018;21:9-10.	MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis.	Revue	Case report d'une présentation atypique d'une patiente MOGAD
Imagerie de la MOGAD			
Ambrosius, W., Michalak, S., Kozubski, W. & Kalinowska, A. Int. J. Mol. Sci. 22, 100 (2020)	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management	Revue	Revue générale sur les patients MOGAD
Armangue, T. et al. Lancet Neurol. 19, 234–246 (2020)	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study	Revue	Revue sur l'atteinte encéphalique chez des enfants MOGAD
Baumann, M. et al. Eur. J. Paediatr. Neurol. 29, 14–21 (2020)	E.U. paediatric MOG consortium consensus: Part 2 – Neuroimaging features of paediatric myelin	Revue secondaire au consensus	Revue complète sur l'atteinte radiologique MOGAD en pédiatrie

	oligodendrocyte glycoprotein antibody-associated disorders	européen pédiatrique	
Baumann, M. et al. J. Neurol. 265, 845–855 (2018)	MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein	Revue	Revue sur l'atteinte radiologique chez les patients MOGAD
Biotti D, Bonneville F, Tournaire E, et al. J Neurol. 2017 Oct;264(10):2173-2175	Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France	Revue	Revue sur les caractéristiques des NO chez les patients MOGAD
Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. J Neurol. 2019 Oct;266(10):2481–7	Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome	Revue	Revue sur les FLAMES chez les patients MOGAD
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, et al. Neurology. 2018 May 22;90(21):e1858–69	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study	Revue	Revue sur les patients adultes MOGAD, facteurs pronostiques et taux d'anticorps anti-MOG
Dubey D, Pittock SJ, Krecke KN et al., JAMA Neurol 2019; 76: 3019-9	Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody	Revue	Revue sur les caractéristiques des myélites chez les patients MOGAD
Gulani, V., Calamante, F., Shellock, F. G., Kanal, E. & Reeder, S. B. Lancet Neurol. 16, 564–570 (2017)	Gadolinium deposition in the brain: summary of evidence and recommendations	Revue	Revue sur les conséquences d'injections répétées de gadolinium
Hacohen, Y. et al. Dev. Med. Child Neurol. 60, 417–423 (2018)	'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease	Revue	Revue sur les caractéristiques des phénotypes « leucodystrophylike » chez les enfants MOGAD
Hennes, E.-M. et al. Neurology 89, 900–908 (2017)	Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome	Revue	Revue sur les conséquences de la positivité des anticorps anti-MOG chez l'enfant
Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). J Neuroinflammation. 2016;13(1):279	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AGP4-IgG, and origin	Revue	Revue générale sur les patients MOGAD
Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). J Neuroinflammation 2016;13(1):280	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome	Revue	Revue générale sur les patients MOGAD
Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). J Neuroinflammation. 2016;13(1):281	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome	Revue	Revue générale sur les patients MOGAD

Ramanathan, S. et al. Mult. Scler. J. 22, 470–482 (2016)	Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis	Revue	Revue comparative des atteintes radiologiques des NMOSD MOG+, AQP4+ et SEP
Song, H. et al. J. Neurol. Sci. 400, 83–89 (2019)	Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: A cohort study in China	Revue	Revue sur l'atteinte NO chez les patients MOGAD
Wendel. EM et al. Eur J Paediatr Neurol. 2020 Jul;27:86-93	High association of MOG-IgG antibodies in children with bilateral optic neuritis.	Revue	Revue sur l'atteinte bilatérale des NO chez les patients MOGAD
Biologie de la MOGAD			
Reindl M. et al. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):e674	International multicenter examination of MOG antibody assays	Revue	Revue sur le dosage des anticorps anti-MOG
Évolution de la MOGAD chez l'adulte			
Akaishi et al. J Neurol. 2021 Nov 25	Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease	Revue	Revue sur les risques de rechute chez les patients MOGAD
Deschamps R, Pique J, Ayrignac X, et al NOMADMUS study group. Eur J Neurol. 2021 May;28(5):1659-1664	The long-term outcome of MOGAD: An observational national cohort study of 61 patients	Revue	Revue sur le devenir des patients MOGAD
Évolution de la MOGAD chez l'enfant			
Bruijstens AL, Breu M, Wendel EM, Wassmer E, Lim M, Neuteboom RF, Wickström R; E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. Eur J Paediatr Neurol. 2020 Nov;29:32-40	E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders	Revue secondaire au consensus européen pédiatrique	Revue complète sur l'évolution des MOGAD en pédiatrie
Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, Wassmer E; E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. Eur J Paediatr Neurol. 2020 Nov;29:2-13	E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders	Revue secondaire au consensus européen pédiatrique	Revue complète sur les atteintes des MOGAD en pédiatrie
Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Ann Neurol. 2021 Jan;89(1):30–41	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease	Revue	Revue générale sur les patients MOGAD

Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E, Wassmer E, Hemingway C, Forsyth R, Hennes EM, Leite MI, Ciccarelli O, Anlar B, Hintzen R, Marignier R, Palace J, Baumann M, Rostásy K, Neuteboom R, Deiva K, Lim M. JAMA Neurol. 2018 Apr 1;75(4):478-487	Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease	Revue	Revue sur l'évolution des patients MOGAD
López-Chiriboga AS, Majed M, Fryer J, et al. J AMA Neurol. 2018;75(11):1355-1363	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders	Revue	Revue sur le lien potentiel entre la positivité des anticorps anti-MOG et le risque de rechute
Waters P, Fadda G, Woodhall M, O'Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network. JAMA Neurol. 2020 Jan 1;77(1):82-93	Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes	Revue	Revue sur le lien potentiel entre la positivité des anticorps anti-MOG et le risque de rechute
Prise en charge thérapeutique des MOGAD chez l'adulte			
Alshamrani F, Alnajashi H, Shosha E, et al. Front Neurol. 2020;11:89	Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum	Revue	Revue sur les similitudes phénotypiques entre SEP et MOGAD
Bellinvia A, Pastò L, Razzolini L, et al. 2019;33:51-54	The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports	Revue	Case report de 3 patients MOGAD
Biotti D, Lerebours F, Bonneville F, et al. Mult Scler. 2018;24(12):1645-1647	Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder	Revue	Revue sur le rituximab chez des patients MOGAD
Bouzar M, Daoudi S, Hattab S, et al. J Neurol Sci. 2017;381:240-244	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients	Revue	Revue sur les NMOSD AQP4 et MOG
Brayo P, Hartsell FL, Skeen M, et al. J Neuroimmunol. 2019;337:577078	The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series.	Revue	Revue générale sur les MOGAD
Chen JJ, Flanagan EP, Bhatti MT, et al. Neurology. 2020;95(2):111-120	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder	Revue	Revue sur les traitements d'entretien pour les MOGAD
Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. J Neurol. 2022 Jan;269(1):159-183.	Rituximab for the treatment of multiple sclerosis: a review	Revue	Revue sur le rituximab dans les SEP

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, et al. Neurology. 2018 May 22;90(21):e1858–69.	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study	Revue	Revue sur les patients adultes MOGAD, facteurs pronostiques et taux d'anticorps anti-MOG.
Cobo-Calvo A, Sepúlveda M, Rollot F, et al. J Neuroinflammation. 2019;16(1):134	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease	Revue	Revue sur les traitements dans les MOGAD
Durozard P, Rico A, Boutiere C, et al. Ann Neurol. 2020;87(2):256-266	Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases	Revue	Revue comparative du rituximab dans les MOGAD et NMOSD AQP4
Etemadifar M, Abbasi M, Salari M, et al. Mult Scler Relat Disord. 2019;27:127-130	Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome	Revue	Revue comparative des NO MOG+ et MOG-
Gutman JM, Kupersmith M, Galetta S, Kister I. J Neurol Sci. 2018;387:170-173	Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures	Revue	Revue générale des NO et épilepsie chez les MOGAD
Hamid SHM, Whittam D, Saviour M, et al. JAMA Neurol. 2018;75(1):65-71	Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease	Revue	Revue comparative des patients MOGAD et NMOSD AQP4+
Höftberger R, Guo Y, Flanagan EP, et al. Acta Neuropathologica. 2020;139(5):875-892	The pathology of central nervous system inflammatory demyelinating disease accompagnying myelin oligodendrocyte glycoprotein autoantibody	Revue	Revue générale sur les MOGAD
Horellou P, Wang M, Keo V, et al. J Neuroimmunol. 2015;289:1-7	Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis	Revue	Revue comparative des paramètres biologiques des MOGAD et SEP et implication thérapeutique potentielle
Inan B, Gocmen R, Vural A, et al. Mult Scler Relat Disord. 2020;44:102376	Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey	Revue	Revue générale sur les MOGAD
Jarius S, Lechner C, Wendel EM, et al. J Neuroinflammation. 2020;17(1):262	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients	Revue	Revue sur les paramètres biologiques des MOGAD et implication thérapeutique potentielle
Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). J Neuroinflammation. 2016;13(1):279	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AGP4-IgG, and origin	Revue	Revue générale sur les MOGAD

Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). J Neuroinflammation 2016;13(1):280.	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome	Revue	Revue générale sur les MOGAD
Jelcic I, Hanson JVM, Lukas S, et al. J Neuroophtalmol. 2019;39(1):3-7	Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis	Revue	Revue sur le pronostic des NO à anticorps anti-MOG
Jurynczyk M, Jacob A, Fujihara K and Palace J. Pract Neurol 2019; 19: 187-95	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations	Revue	Revue générale sur les MOGAD
Kaneko K, Sato DK, Nakashima I, et al. J Neurol Neurosurg Psychiatry 2018;89:927-936.	CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications	Revue	Revue comparative des LCR des MOGAD, NMOSD AQP4+ et SEP
Kitley J, Woodhall M, Waters P, et al. Neurology. 2012;79(12):1273-1277	Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype	Revue	Revue générale sur les MOGAD
Kothur K, Wienholt L, Tantsis EM, et al. PLoS One. 2016;11(2):e0149411	B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination	Revue	Revue sur les paramètres biologiques des MOGAD et implication thérapeutique potentielle
Kwon YN, Kim B, Ahn S, et al. J Neuroimmunol. 2020;348:577361	Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)	Revue	Revue sur les paramètres biologiques des MOGAD et implication thérapeutique potentielle
Li S, Ren H, Xu Y, et al. Neurology Neuroimmunology Neuroinflammation. 2020;7(3)	Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders - A prospective study	Revue	Revue sur les paramètres biologiques des MOGAD
López-Chiriboga AS, Majed M, Fryer J, et al. JAMA Neurol. 2018;75(11):1355-1363	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders	Revue	Revue sur l'évolution des MOGAD
Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, et al. Neuroophtalmology. 2020;44(1):1-4	Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis	Revue	Case report de 2 patients avec périnévrite optique à anticorps anti-MOG+
Loss J. et al. J Neurol. 2020; 267(6): 1632–1642.	MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation	Revue	Revue sur les myélites étendues dans les MOGAD

Lotan I, Charlson RW, Ryerson LZ, et al. Mult Scler Relat Disord. 2019;39:101920	Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders	Revue	Revue sur le tocilizumab dans les NMOSD
Lu Q, Luo J, Hao H, et al. J Neurol. 2020.	Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis	Revue	Revue de la littérature sur l'utilisation des immunothérapies dans les MOGAD
Montcuquet A, Collongues N, Papeix C, et al. Mult Scler. 2017;23(10):1377-1384	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders	Revue	Revue sur le mycophénolate mofétil dans les MOGAD, NMOSD AQP4 et NMOSD séronégative
Motamedi S, Oertel FC, Yadav SK, Kadas EM, Weise M, Havla J, Ringelstein M, and al. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 23;7(5):e805.	Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders	Revue	Revue sur les NMOSD AQP4+
Pedapati R, Bhatia R, Singh N, et al. J Neuroimmunol. 2020;340:577143	Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum – A north Indian tertiary care centre experience and review of literature	Revue	Revue générale sur les MOGAD
Ramanathan S, Mohammad S, Tantsis E, et al. J Neurol Neurosurg Psychiatr. 2018;89(2):127-137.	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination	Revue	Revue générale sur les MOGAD
Ren Y, Chen X, He Q, et al. Front Neurol. 2019;10:1271	Co-occurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Anti-myelin Oligodendrocyte Glycoprotein Inflammatory Demyelinating Diseases: A Clinical Phenomenon to Be Taken Seriously	Revue	Case report de 4 patients doublement séropositifs NMDA-R et MOG
Rigal J, Pugnet G, Ciron J, et al. 2020;46:102483	Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series	Revue	Revue sur l'utilisation du tocilizumab dans les pathologies démyélinisantes du SNC
Tao R, Qin C, Chen M, et al. Int J Neurosci. 2020;130(11):1161-1165	Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders	Revue	Case report de 2 patients avec encéphalite corticale à anticorps anti-MOG+
Tsantes E, Curti E, Siena E, Granella F. Mult Scler Relat Disord. 2019;32:27-29	Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease	Revue	Case report d'un patient MOGAD traité par cure d'Ig IV
Tzartos JS, Karagiorgou K, Tzanetakos D, et al. J Neurol Sci. 2020;410:116673	Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays	Revue	Revue comparative de 3 méthodes de détection des anticorps anti-MOG
Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Mult Scler Relat Disord. 2020;44:102251	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients	Revue	Revue sur l'utilisation du rituximab dans les MOGAD

Prise en charge thérapeutique des MOGAD chez l'enfant			
Bruijstens AL, Wendel EV, Lechner C et al. European Journal of Paediatric Neurology. 2020, 29 41-53. doi.org/10.1016/j.ejpn.2020.10.005	E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders	Revue secondaire au consensus européen pédiatrique	Revue complète sur les thérapeutiques chez les enfants atteints de MOGAD
Padmanabhan A, Connelly-Smith L, Aqui N et al. J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705. PMID: 31180581	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.	Revue	Revue générale sur les plasmaphérèses
Grossesse et MOGAD			
Collongues N, Alves Do Rego C, Bourre B et al. Neurology 2021;96(15):e2006-15.	Pregnancy in patients with AQP4-Ab, MOG-AB, or double-negative neuromyelitis optica disorder.	Revue	Revue comparative de femmes enceintes atteintes de MOGAD, NMOSD AQP4+ et NMOSD séronégative
Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). J Neuroinflammation 2016;13(1):280.	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.	Revue	Revue générale sur les MOGAD
Wang L, Zhou L, ZhangBao J et al. J Neurol Neurosurg Psychiatry 2021;92:53-61.	Neuromyelitis optica spectrum disorders: pregnancy-related attack and predictive factors.	Revue	Revue comparative de femmes enceintes atteintes de MOGAD et NMOSD AQP4+

Annexe 1. Recherche documentaire et sélection des articles

Recherche documentaire

Sources consultées	Bases de données : PUBMED Sites internet : PUBMED
Période de recherche	Non limitée dans le temps
Langues retenues	Anglais et français
Mots clés utilisés	MOGAD, neuromyelitis, neuromyelitis optica, NMOSD
Nombre d'études recensées	> 200
Nombre d'études retenues	110

Critères de sélection des articles

Selon le type de la publication et le thème traité.

Annexe 2. Liste des participants

Ce travail a été coordonné par le Pr Kumaran Deiva, coordonnateur du Centre de Référence des Maladies Inflammatoires Rares du Cerveau Et de la Moelle (MIRCEM) et le Pr Romain Marignier, responsable du site constitutif MIRCEM de Lyon.

Ont participé à l'élaboration du PNDS :

Groupe multidisciplinaire rédactionnel
Pr Kumaran Deiva, neuropédiatre, CHU Kremlin Bicêtre
Pr Romain Marignier, neurologue, Hospices Civils de Lyon
Dr Caroline Papeix, neurologue, CHU Pitié Salpêtrière
Dr Hélène Maurey, neuropédiatre, CHU Kremlin Bicêtre
Dr Jonathan Ciron, neurologue, CHU Toulouse
Dr Nicolas Collongues, neurologue, CHRU Strasbourg
Dr Emmanuel Cheuret, neuropédiatre, CHU Toulouse
Pr Hélène Zephir, neurologue, CHU Lille
Dr Elisabeth Maillart, neurologue, CHU Pitié Salpêtrière
Dr Pierre Meyer, neuropédiatre, CHU de Montpellier
Pr Sandra Vukusic, neurologue, Hospices Civils de Lyon
Pr Muriel Doret-Dion, gynécologue, obstétricien, Hospices Civils de Lyon
Dr Julie Pique, neurologue, Hospices Civils de Lyon
Dr Marie Thérèse Abiwarde, neuropédiatre, CHU Strasbourg
Dr Anne Lise Poulat, neuropédiatre, CHU Lyon
Dr Emmanuel Barreau, ophtalmologue, CHU Kremlin Bicêtre
Dr Romain Deschamps, neurologue, Fondation Rothschild
Pr Bertrand Audoin, neurologue, CHU Marseille
Dr Mannes Inès, radiopédiatre, CHU Kremlin Bicêtre
Dr Laetitia Giorgi, neuropédiatre, CHU Kremlin Bicêtre
Mme Evelyne Yver, assistante sociale, CHU Kremlin Bicêtre
Mme Carole Lattaud, assistante sociale, CHU Pitié Salpêtrière

Groupe de relecture
Pr Caroline Froment Tilikete
Dr Marie-Caroline Pouget
Pr Sylvie Nguyen The Tich
Dr Bertrand Bourre
Pr Jérôme de Seze
Mme Marine Gelé
Mme Souad Mazari, présidente de l'association NMO France
Mme Léa Coqueron, patiente
Mme Gwladys Desmars, patiente
Mme Christelle Clairon, patiente
Mme Bérengère Steinberg, mère d'une patiente

Gestion des intérêts déclarés

Tous les participants à l'élaboration du PNDS ont rempli une déclaration d'intérêt. Les déclarations d'intérêt sont en ligne et consultables sur le site internet du centre de référence des maladies inflammatoires rares du cerveau et de la moelle (www.mircem.fr) et sur le site internet de la filière de santé maladies rares BRAIN-TEAM (www.brain-team.fr).

Les déclarations d'intérêt ont été analysées et prises en compte, en vue d'éviter les conflits d'intérêts, conformément au guide HAS « Guide des déclarations d'intérêts et de gestion des conflits d'intérêts » (HAS, 2010).

Modalités de concertation du groupe de travail multidisciplinaire

Réunions par visioconférence : 21/05/2021, 21/12/2021, 31/03/2022
Nombreux échanges par e-mails.

Références bibliographiques

Biotti D, Bonneville F, Tournaire E, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017 Oct;264(10):2173-2175.

Bruijstens AL, Breu M, Wendel EM, Wassmer E, Lim M, Neuteboom RF, Wickström R; E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:32-40.

Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, Wassmer E; E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13

Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018 Nov;195:8-15.

Cheuret E, Meyer P, Varenne F et al. Prise en charge de la neuropathie optique inflammatoire de l'enfant. Journal de Pédiatrie et de Puériculture. 2021 june, 34 : 115-121.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018 May 22;90(21):e1858–69.

Deschamps R, Pique J, Ayrignac X, et al NOMADMUS study group. The long-term outcome of MOGAD: An observational national cohort study of 61 patients. Eur J Neurol. 2021 May;28(5):1659-1664.

Ducloyer JB, Caignard A, Aidaoui R, et al. MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis. Br J Ophthalmol. 2020 Jun;104(6):842-845..

Havla J. et al. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J. Neuroinflammation 18, 121 (2021).

Kohji Azumagawa K et al, A nation-wide survey of Japanese pediatric MOG antibody-associated diseases, Brain and Development, 2021 June; 43 (6):705-713.

Korobelnik JF. OCT en ophtalmologie: rapport 2019 / [présenté à la] Société française d'ophtalmologie ; [dirigé] par Jean-François Korobelnik ; avec la collaboration de Émilie Agard, Fadoua Aharchi, Florent Aptel... [et al.]. (Elsevier Masson, 2019).

Lotan I, Brody J, Hellmann MA, et al. Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. J Neurol. 2018 Sep;265(9):1985-1988.

Merabtene L, Vignal Clermont C, Deschamps R. Neuropathie optique dans le syndrome des anticorps anti MOG positif [Optic neuropathy in positive anti-MOG antibody syndrome]. J Fr Ophtalmol. 2019 Dec;42(10):1100-1110.

Shor N, Aboab J, Maillart E, et al. Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. Eur J Neurol. 2020 Feb;27(2):384-391

Toanen V, Vignal-Clermont C (2016) Neuropathies optiques inflammatoires. //www.em-premium.com/data/traites/op/21-71372.

Vignal-Clermont C. Neuro-ophtalmologie pratique, rapport SFO 2020. (Elsevier Masson).

Vosoughi AR, Ling J, Tam KT, et al. Br J Ophthalmol Epub ahead of print: [please include Day Month Year]. doi:10.1136/ bjophthalmol-2020- 317267

Wendel. EM et al. High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur J Paediatr Neurol. 2020 Jul;27:86-93

Absoud M, Greenberg BM, Lim M, Lotze T, Thomas T, Deiva K. Pediatric transverse myelitis. Neurology. 2016;87(9 Suppl 2):S46-S52

Chien C, Scheel M, Schmitz-Hübsch T et al., Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler 2019; 25: 1926-36

Ciron J, Cobo-Calvo A, Audoin B et al., Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Mult Scler 2020; 26: 936-44

Dubey D, Pittock SJ, Krecke KN et al., Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019; 76: 3019-9

Group TMCW. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505.

Jurynczyk M, Jacob A, Fujihara K and Palace J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol 2019; 19: 187-95

Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128-3138.

Kitley J, Waters P, Woodhall M et al., Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-83

Lechner C, Baumann M, Hennes E-M, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatr. 2016;87(8):897-905.

Macaron G and Ontaneda D. MOG-related disorders: A new cause of imaging-negative myelitis? Mutl Scler 2020; 26: 515-15

Maynard FM, Bracken MB, Creasey G, et al. International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association. Spinal Cord. 1997;35(5):266-274

Rabasté S, Cobo-Calvo A, Nistiriuc-Muntean V et al., Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. J Neuroradiol 2021; 48: 28-36

Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatr. 2018;89(2):127-137.
Sato DK, Callegaro D, Lana-Peixoto MA et al., Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurol 2014; 82: 474-81

Sechi E, Krecke KN, Pittock SJ et al., Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler 2021; 27: 303-308

Shor N, Deschamps R, Cobo Calvo A, Maillart E, Zephir H, Ciron J, et al. MRI characteristics of MOG-Ab associated disease in adults: An update. Rev Neurol (Paris). 2021 Jan;177(1–2):39–50.

Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265–72.

Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome.
J Neurol. 2019 Oct;266(10):2481–7.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018 May 22;90(21):e1858–69.

Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol. 2021 Jan;89(1):30–41.

Fadda G, Banwell B, Waters P, Marrie RA, Yeh EA, O'Mahony J, et al. Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease. Ann Neurol. 2021 Feb;89(2):408–13

Fujimori J, Nakamura M, Yagihashi T, Nakashima I. Clinical and Radiological Features of Adult Onset Bilateral Medial Frontal Cerebral Cortical Encephalitis With Anti-myelin Oligodendrocyte Glycoprotein Antibody. Front Neurol. 2020 Dec 16;11:600169

Netravathi M, Holla VV, Nalini A, Yadav R, Vengalil S, Oommen AT, et al. Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. J Neurol. 2021 Apr;268(4):1419–33.

Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol - Neuroimmunol Neuroinflammation. 2017 Mar;4(2):e322.
Ramberger M, Bsteh G, Schanda K, Höftberger R, Rostásy K, Baumann M, et al. NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases. Neurol - Neuroimmunol Neuroinflammation. 2015 Oct;2(5):e141.

Shor N, Deschamps R, Cobo Calvo A, Maillart E, Zephir H, Ciron J, et al. MRI characteristics of MOG-Ab associated disease in adults: An update. Rev Neurol (Paris). 2021 Jan;177(1–2):39–50.

Yazbeck E, Maurey H, Leroy C, Horellou P, Napuri S, Lali M, et al. Progressive Leukodystrophy-Like Demyelinating Syndromes with MOG-Antibodies in Children: A Rare Under-Recognized Phenotype. Neuropediatrics. 2021 Aug;52(4):337–40

Banks SA, Morris PP, Chen JJ, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry 2020.

Berzero G, Taieb G, Marignier R, et al. CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies. Eur J Neurol 2018;25:e16-e17

Cobo-Calvo A, Ayrignac X, Kerschen P, et al. Cranial nerve involvement in patients with MOG antibody-associated disease. Neurol Neuroimmunol Neuroinflamm 2019;6:e543.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018 May 22;90(21):e1858–69.

Fujimori J, Takahashi T, Matsumoto Y, et al. Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behcet's disease. J Neuroimmunol 2019;334:577002.

Jarius S, Kleiter I, Ruprecht K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation 2016;13:281.

Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 2018;89:927-936.

Kunchok A, Krecke KN, Flanagan EP, et al. Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? Neurology 2020;94:85-88.

Rinaldi S, Davies A, Fehmi J, et al. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm 2021;8.

Salama S, Khan M, Levy M, Izbudak I. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord 2019;29.

Shen Y, Cheng Z, Zhou C. Bilateral trigeminal root entry zone enhancement in MOG-IgG-associated brainstem encephalitis. Neurol Sci 2019;40:1083-1085.

Taieb G, Labauge P. Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS. Neurology 2015;85:1262-1263.

Vecchio D, Virgilio E, Naldi P, Comi C, Cantello R. MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. Mult Scler Relat Disord 2018;21:9-10.

Ambrosius, W., Michalak, S., Kozubski, W. & Kalinowska, A. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. Int. J. Mol. Sci. 22, 100 (2020).

Armangue, T. et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 19, 234–246 (2020).

Baumann, M. et al. E.U. paediatric MOG consortium consensus: Part 2 – Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur. J. Paediatr. Neurol. 29, 14–21 (2020).

Baumann, M. et al. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J. Neurol. 265, 845–855 (2018).

Biotti D, Bonneville F, Tournaire E, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017 Oct;264(10):2173-2175.

Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol. 2019 Oct;266(10):2481–7.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018 May 22;90(21):e1858–69.

Dubey D, Pittock SJ, Krecke KN et al., Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019; 76: 3019-9

Gulani, V., Calamante, F., Shellock, F. G., Kanal, E. & Reeder, S. B. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 16, 564–570 (2017).

Hacohen, Y. et al. 'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. Dev. Med. Child Neurol. 60, 417–423 (2018).

Hennes, E.-M. et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89, 900–908 (2017).

Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AGP4-IgG, and origin. J Neuroinflammation. 2016;13(1):279

Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13(1):280.

Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13(1):281

Ramanathan, S. et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult. Scler. J. 22, 470–482 (2016).

Song, H. et al. Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: A cohort study in China. J. Neurol. Sci. 400, 83–89 (2019).

Wendel. EM et al. High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur J Paediatr Neurol. 2020 Jul;27:86-93

Reindl M. et al. International multicenter examination of MOG antibody assays, Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):e674.

Akaishi et al. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. J Neurol. 2021 Nov 25.

Deschamps R, Pique J, Ayrignac X, et al NOMADMUS study group. The long-term outcome of MOGAD: An observational national cohort study of 61 patients. Eur J Neurol. 2021 May;28(5):1659-1664

Bruijstens AL, Breu M, Wendel EM, Wassmer E, Lim M, Neuteboom RF, Wickström R; E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:32-40.

Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, Wassmer E; E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13

Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol. 2021 Jan;89(1):30–41.

Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E, Wassmer E, Hemingway C, Forsyth R, Hennes EM, Leite MI, Ciccarelli O, Anlar B, Hintzen R, Marignier R, Palace J, Baumann M, Rostásy K, Neuteboom R, Deiva K, Lim M. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2018 Apr 1;75(4):478-487.

López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol. 2018;75(11):1355-1363

Waters P, Fadda G, Woodhall M, O'Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes.JAMA Neurol. 2020 Jan 1;77(1):82-93.

Alshamrani F, Alnajashi H, Shosha E, et al. Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum. Front Neurol. 2020;11:89
Bellinvia A, Pastò L, Razzolini L, et al. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports. 2019;33:51-54

Biotti D, Lerebours F, Bonneville F, et al. Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder. Mult Scler. 2018;24(12):1645-1647

Bouzar M, Daoudi S, Hattab S, et al. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. J Neurol Sci. 2017;381:240-244

Brayo P, Hartsell FL, Skeen M, et al. The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series. J Neuroimmunol. 2019;337:577078

Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):111-120

Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple

sclerosis: a review. J Neurol. 2022 Jan;269(1):159-183.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018 May 22;90(21):e1858–69.

Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019;16(1):134

Durozard P, Rico A, Boutiere C, et al. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. Ann Neurol. 2020;87(2):256-266

Etemadifar M, Abbasi M, Salari M, et al. Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome. Mult Scler Relat Disord. 2019;27:127-130

Gutman JM, Kupersmith M, Galetta S, Kister I. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures. J Neurol Sci. 2018;387:170-173

Hamid SHM, Whittam D, Saviour M, et al. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. JAMA Neurol. 2018;75(1):65-71

Höftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompagnying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathologica. 2020;139(5):875-892

Horellou P, Wang M, Keo V, et al. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis. J Neuroimmunol. 2015;289:1-7

Inan B, Gocmen R, Vural A, et al. Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey. Mult Scler Relat Disord. 2020;44:102376

Jarius S, Lechner C, Wendel EM, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. J Neuroinflammation. 2020;17(1):262

Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AGP4-IgG, and origin. J Neuroinflammation. 2016;13(1):279

Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13(1):280.

Jelcic I, Hanson JVM, Lukas S, et al. Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. J Neuroophtalmol. 2019;39(1):3-7

Jurynczyk M, Jacob A, Fujihara K and Palace J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol 2019; 19: 187-95

Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 2018;89:927-936.

Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79(12):1273-1277

Kothur K, Wienholt L, Tantsis EM, et al. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination. PLoS One. 2016;11(2):e0149411

Kwon YN, Kim B, Ahn S, et al. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). J Neuroimmunol. 2020;348:577361

Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders - A prospective study. Neurology Neuroimmunology Neuroinflammation. 2020;7(3)

López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol. 2018;75(11):1355-1363

Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, et al. Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. Neuroophtalmology. 2020;44(1):1-4

Loss J. et al. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. J Neurol. 2020; 267(6): 1632–1642.

Lotan I, Charlson RW, Ryerson LZ, et al. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;39:101920

Lu Q, Luo J, Hao H, et al. Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. J Neurol. 2020.

Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377-1384

Motamedi S, Oertel FC, Yadav SK, Kadas EM, Weise M, Havla J, Ringelstein M, Aktas O,Albrecht P, Ruprecht K, Bellmann-Strobl J, Zimmermann HG, Paul F, Brandt AU. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 23;7(5):e805.

Pedapati R, Bhatia R, Singh N, et al. Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum – A north Indian tertiary care centre experience and review of literature. J Neuroimmunol. 2020;340:577143

Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatr. 2018;89(2):127-137.

Ren Y, Chen X, He Q, et al. Co-occurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Anti-myelin Oligodendrocyte Glycoprotein Inflammatory Demyelinating Diseases: A Clinical Phenomenon to Be Taken Seriously. Front Neurol. 2019;10:1271

Rigal J, Pugnet G, Ciron J, et al. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series. 2020;46:102483

Tao R, Qin C, Chen M, et al. Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders. Int J Neurosci. 2020;130(11):1161-1165

Tsantes E, Curti E, Siena E, Granella F. Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. Mult Scler Relat Disord. 2019;32:27-29

Tzartos JS, Karagiorgou K, Tzanetakos D, et al. Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. J Neurol Sci. 2020;410:116673

Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251

Bruijstens AL, Wendel EV, Lechner C et al. E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders, European Journal of Paediatric Neurology. 2020, 29 41-53. doi.org/10.1016/j.ejpn.2020.10.005

Padmanabhan A, Connelly-Smith L, Aqui N et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705. PMID: 31180581

Collongues N, Alves Do Rego C, Bourre B et al. Pregnancy in patients with AQP4-Ab, MOG-AB, or double-negative neuromyelitis optica disorder. Neurology 2021;96(15):e2006-15.

Jarius S, Ruprecht K, Kleiter I et al for the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13(1):280.

Wang L, Zhou L, ZhangBao J et al. Neuromyelitis optica spectrum disorders: pregnancy-related attack and predictive factors. J Neurol Neurosurg Psychiatry 2021;92:53-61.